Hafsteinsdóttir, Brynhildur http://orcid.org/0000-0001-7889-8453
Farman, Helen
Lagerström, Nina
Zetterberg, Henrik
Andersen, Oluf
Novakova, Lenka
Nellgård, Bengt
Rosén, Hans
Malmeström, Clas
Rosenstein, Igal
Lycke, Jan
Axelsson, Markus
Funding for this research was provided by:
Stiftelsen Edit Jakobssons Donationsfond
Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
Swedish Foundation for MS Research
Göteborgs Läkaresällskap
Berit Linnea and Ragnar Bakken Foundation
Swedish State Support for Clinical Research (ALFGBG-722081)
University of Gothenburg
Article History
Received: 9 May 2024
Revised: 25 August 2024
Accepted: 31 August 2024
First Online: 9 September 2024
Declarations
:
: HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JL has received travel support and/or lecture honoraria and has served on scientific advisory boards for Amgen, Almirall, Biogen, Bristol Myers Squibb, Celgene, Genesis Pharma, Janssen, Merck, Novartis, Roche, Sanofi and Sandoz; and has received unconditional research grants from Biogen and Novartis, and financial research support from Sanofi. LN has received lecture honoraria from Biogen, Novartis, Teva, Sanofi, Merck and has served on advisory boards for Merck, Janssen and Sanofi.